More importantly, targeting PDGFRA with its selective inhibitor avapritinib, significantly enhanced the sensitivity of liver cancer cells to lenvatinib, a result that has also been verified in patient-derived organoid (PDO) models and patient-derived xenograft (PDX) mouse models. The gene discussed is PDGFRA; the disease is liver cancer.